Acne
Actinic Keratosis
Aesthetics
Alopecia
Atopic Dermatitis
Buy-and-Bill
COVID-19
Case-Based Roundtable
Chronic Hand Eczema
Drug Watch
Eczema
General Dermatology
Hidradenitis Suppurativa
Melasma
NP and PA
Pediatric Dermatology
Pigmentary Disorders
Practice Management
Precision Medicine and Biologics
Prurigo Nodularis
Psoriasis
Psoriatic Arthritis
Rare Disease
Rosacea
Skin Cancer
Vitiligo
Wound Care

News

Article

March 28, 2025

Daily Derm Times: March 28, 2025

Author(s):

Emma Andrus, Editor

Key Takeaways

A fixed-dose acne treatment gel combining clindamycin phosphate, adapalene, and benzoyl peroxide is effective for Hispanic patients with moderate to severe lesions.
Machine learning is improving laser treatment planning, ensuring safer and more effective procedures through AI-based skin assessments.
Undersleeping, along with smoking, alcohol consumption, and sedentary behavior, is identified as a potential risk factor for cutaneous melanoma.
The top articles of March included insights on recalls and expert advice, with the print issue offering in-depth coverage of these topics.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Dermatology Times March 2025 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of March.

Fixed-Dose Acne Treatment Gel is Safe and Effective for Hispanic Patients, According to Post-Hoc Analysis

The therapy, which combines clindamycin phosphate, adapalene, and benzoyl peroxide, was effective for Hispanic patients with moderate to severe lesions.

Machine Learning Enhances Laser Treatment Planning

With an increasing demand for laser procedures, AI-based skin assessments may help ensure safer and more effective treatments.

Undersleeping is a Potential Risk Factor for Cutaneous Melanoma

Two-sample Mendelian randomization analysis explored lifestyle factors such as sleep, smoking, alcohol consumption, and sedentary behavior.

Review and Meta-Analysis Compares Delgocitinib to Vehicle for Chronic Hand Eczema Treatment

Patients with CHE saw higher treatment success and a favorable safety profile with delgocitinib 20-30 mg/g.

Dermatology Times March 2025 Print Recap

Learn more about the in-depth topics covered in the March 2025 print issue of Dermatology Times.